Bibliographic Details
| Title: |
Choosing a First Drug Treatment for Epilepsy after SANAD: Randomized Controlled Trials, Systematic Reviews, Guidelines and Treating Patients. |
| Authors: |
Chadwick, David, Marson, Tony |
| Source: |
Epilepsia (Series 4). Jul2007, Vol. 48 Issue 7, p1259-1263. 5p. |
| Subjects: |
Anticonvulsants, Epilepsy, Randomized controlled trials, Clinical pharmacology, Carbamazepine |
| Abstract: |
The ILAE treatment guidelines for initial monotherapy emphasise the poor quality of information available to inform everyday clinical practice. Industry sponsored studies comparing antiepileptic drugs answer restricted licensing questions, rather than those relevant to the clinical community (patients, health professionals and funders of health care). The SANAD study, a pragmatic randomized clinical trial, offers a methodology to address some of these questions. It identifies lamotrigine as a cost-effective alternative to carbamazepine for the treatment of focal epilepsies, but confirms valproate as the most effective drug for the treatment of generalized or unclassified epilepsy. [ABSTRACT FROM AUTHOR] |
|
Copyright of Epilepsia (Series 4) is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Psychology and Behavioral Sciences Collection |
